The latest updates on Ozempic, Mounjaro, Wegovy and GLP-1 treatments
Scientists are studying whether semaglutide might influence aging processes beyond weight loss. Here is what the research actually shows and what it means for people considering these medications.
Curious how ANVISA regulates weight loss pens in Brazil? Learn the two approval pathways, how to verify if a drug is legal, and what new approvals mean for your access.
Eli Lilly is exploring an oral version of tirzepatide, but peptide pills face significant scientific hurdles. Here's what we know about the possibility of a Mounjaro or Zepbound pill.
Brazil's medical council issued a formal warning about unregistered tirzepatide. Here's what this alert means for healthcare providers and patients seeking GLP-1 treatments.
The FDA just expanded Mounjaro's label to include cardiovascular risk reduction. Here's what Brazilian patients with diabetes need to know about what changed, what it means for treatment decisions, and how close Brazil is to following suit.
Curious about switching from Ozempic to an EMS generic semaglutide in Brazil? Learn what differentiates them, what ANVISA approval means, and what to discuss with your doctor.
A recent Brazilian court ruling ordered SUS to provide Mounjaro to a patient. Here's what that decision means for health insurance coverage and GLP-1 access in Brazil.
If you're looking into Mounjaro (tirzepatide) in the United States, you've probably noticed the confusing maze of pricing, prescriptions, and online offers. Here's what you actually need to know.
New research suggests GLP-1 weight loss medications may reduce inflammation beyond what weight loss alone explains. Here is what the science currently supports.
Hypera Pharma's new Semavy pen enters Brazil's GLP-1 market at a competitive price point. Here's what to consider before making the switch.
Answer a few quick questions and get tailored guidance for your treatment.
or download the app
